Infliximab
Indication
Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line
Red
Brand:
Remicade®, Inflectra®, Remsima®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
Infliximab or golimumab may be used as a second line biologic in UC ONLY where patients have had adalimumab 1st line.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: